Revenue: As of FY2025 Q2, the actual value is USD 70.59 K, beating the estimate of USD 35 K.EPS: As of FY2025 Q2, the actual value is USD -0.1.EBIT: As of FY2025 Q2, the actual value is USD -1.621 M, beating the estimate of USD -2.3 M.<h3>Segment Revenue</h3><ul><li>Total Revenues: For the three months ended June 30, 2025, total revenues were $70,588, compared to $26,840 for the same period in 2024, representing a 163% increase.</li><li>Six Months Revenue: For the six months ended June 30, 2025, total revenues were $111,603, compared to $105,511 for the same period in 2024, representing a 6% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended June 30, 2025, net loss was - $1,580,987, compared to - $1,284,493 for the same period in 2024, representing a 23% increase.</li><li>Six Months Net Loss: For the six months ended June 30, 2025, net loss was - $3,569,324, compared to - $2,325,650 for the same period in 2024, representing a 53% increase.</li><li>Gross Profit: For the three months ended June 30, 2025, gross profit was $47,750, compared to $19,593 for the same period in 2024, representing a 144% increase.</li><li>Six Months Gross Profit: For the six months ended June 30, 2025, gross profit was $75,207, compared to $89,108 for the same period in 2024, representing a 16% decrease.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was - $2,343,379, compared to - $2,009,704 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $4,646,397, compared to $0 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Customer Concentration: Two customers accounted for 85% of revenues for the three months ended June 30, 2025, while six customers accounted for 90% of revenues for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Nexalin plans to conduct clinical trials for the Gen-2 SYNC and Gen-3 HALO devices in the U.S. and continue consulting with the FDA as part of the pre-submission process. If FDA clearance is obtained, commercialization of these devices for sale in the U.S. and other territories will begin.</li><li>Non-Core Business: The company is focusing on expanding its market presence in China through its joint venture with Wider Come Limited, which has been approved by the China National Medical Products Administration for marketing and sale of the Gen-2 device for insomnia and depression.</li></ul>

Nexalin Tech | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 70.59 K